Vericel VCEL

Biotechnology, Healthcare

$42.53

−1.02%

Market cap: $2.2B
PE: 92.5×; 5y median 158×
Forward PE: n/m; not a meaningful number
Price to sales: 7.1×
EV/EBIT: 116×
Revenue, 12 months: $306.3M; +23% on a year ago
Net margin: 7.9%
Free cash flow yield: 2.8%

Vericel trades at 92.5× trailing earnings, cheaper than 84% of the last ten years. Revenue was $306.3M over the last twelve months, up 23% on a year earlier with a 8% net margin.

Charts

Financials

Income statement for VCEL, by quarter
Income statement	Q3 FY23	Q4 FY23	Q1 FY24	Q2 FY24	Q3 FY24	Q4 FY24	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
	$45.6M+18%	$65M+23%	$51.3M+25%	$52.7M+15%	$57.9M+27%	$75.4M+16%	$52.6M+3%	$63.2M+20%	$67.5M+17%	$92.9M+23%	$68.4M+30%	$77.5M+23%
Cost of revenue	$15M+12%	$16.5M+14%	$15.9M+10%	$16.1M+1%	$16.3M+9%	$16.9M+2%	$16.3M+3%	$16.6M+4%	$17.9M+10%	$19.8M+17%	$19.2M+17%	$21.1M+27%
Gross profit	$30.6M+21%	$48.5M+27%	$35.4M+33%	$36.6M+22%	$41.7M+36%	$58.5M+21%	$36.3M+3%	$46.6M+27%	$49.6M+19%	$73.1M+25%	$49.3M+36%	$56.4M+21%
R&D	$5.7M+13%	$4.9M−7%	$6.4M+23%	$7.4M+40%	$6.1M+7%	$4.9M+0%	$7.3M+13%	$6.7M−9%	$6.3M+4%	$7.3M+47%	$8.1M+12%	$7.5M+11%
SG&A	$30M+11%	$30.9M+15%	$34.4M+17%	$35.3M+15%	$38M+27%	$35.1M+14%	$41.8M+22%	$41.9M+19%	$39.8M+5%	$43.5M+24%	$49.2M+18%	$48.5M+16%
	−$5.1M−26%	$12.7M+109%	−$5.5M−33%	−$6M+1%	−$2.5M−51%	$18.5M+45%	−$12.8M+134%	−$2M−66%	$3.5M	$22.4M+21%	−$8.1M−37%	$434K
Interest expense	$150K+43%	$156K−30%	$153K+6%	$153K+3%	$154K+3%	$154K−1%	$153K+0%	$157K+3%	$158K+3%	$162K+5%	$160K+5%	$160K+2%
Pre-tax income	−$3.9M−40%	$14.1M+113%	n/a	n/a	−$901K−77%	$20M+42%	n/a	n/a	n/a	n/a	n/a	n/a
	−$286K	$1.1M+57%	n/a	n/a	$0	$148K−87%	n/a	n/a	n/a	n/a	n/a	n/a
Net income	−$3.7M−44%	$13M+119%	−$3.9M−49%	−$4.7M−7%	−$901K−75%	$19.8M+52%	−$11.2M+191%	−$553K−88%	$5.1M	$23.2M+17%	−$6.3M−44%	$2.2M
	−$0.08−43%	$0.27+108%	−$0.08−50%	−$0.10−9%	−$0.02−75%	$0.38+41%	−$0.23+188%	−$0.01−90%	$0.10	$0.44+16%	−$0.12−48%	$0.04
	47.6M+1%	47.7M+1%	48.1M+2%	48.7M+2%	49.1M+3%	52.3M+10%	49.9M+4%	50.4M+4%	51.9M+6%	52.4M+0%	50.8M+2%	52.3M+4%

Gross profit: 11 periods, Q1 FY11 to Q4 FY13: not printed by the filing, worked out from its own lines.

Net income: 4 periods, Q3 FY10 to Q4 FY11: not printed by the filing, worked out from its own lines.

EPS, diluted: 11 periods, Q4 FY10 to Q4 FY25: quarter's net income to common over its shares, to the cent.

Diluted shares: Q4 FY10: a loss quarter: its basic count, share-days: the 6-month average less the 3-month, weighted by days. 6 periods, Q4 FY11 to Q4 FY16: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. 6 periods, Q4 FY17 to Q4 FY23: share-days: the 12-month average less the 9-month, weighted by days. 3 periods, Q4 FY20 to Q4 FY25: the earlier year to date counted no dilution: the quarter's basic count plus the later year to date's dilution.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Peers

Companies in Biotechnology nearest Vericel's size, closest first.

Company	Market cap	PE	Its 10y median PE	P/S	Revenue growth	Net margin
VCELVericel	$2.2B	92.5×	158×	7.1×	+23%	7.9%
ADMAAdma Biologics	$2.4B	15.3×	21.5×	4.7×	+8%	33.0%
MGTXMeiraGTx	$884.6M	13.0×	18.0×	2.2×	n/m	19.9%
KRYSKrystal Biotech	$9.2B	39.0×	42.7×	20.9×	+23%	54.8%
RGENRepligen	$10B	242×	120×	12.7×	+16%	5.3%
TECHBIO-TECHNE	$11.4B	63.1×	61.6×	9.4×	−0%	15.0%
HALOHalozyme Therapeutics	$14.3B	37.5×	21.3×	8.6×	+41%	24.9%
NBIXNeurocrine Biosciences	$14.5B	20.9×	42.8×	4.3×	+34%	20.9%
EXELExelixis	$16B	20.3×	22.8×	6.6×	+9%	35.3%
Peer median	$10.7B	29.2×	32.7×	7.6×	+16%	22.9%